Linked Life Data

14978008

Source:http://linkedlifedata.com/resource/pubmed/id/14978008

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-6-28
pubmed:abstractText
This study tested whether alpha-adrenoceptor-mediated coronary vasoconstriction is augmented during exercise in diabetes mellitus. Experiments were conducted in dogs instrumented with catheters in the aorta and coronary sinus and with a flow transducer around the circumflex coronary artery. Diabetes was induced with alloxan monohydrate (n = 8, 40 mg/kg i.v.). Arterial plasma glucose concentration increased from 4.7 +/- 0.2 mM in nondiabetic, control dogs (n = 8) to 21.4 +/- 1.9 mM 1 wk after alloxan injection. Coronary blood flow, myocardial oxygen consumption (MVo(2)), aortic pressure, and heart rate were measured at rest and during graded treadmill exercise before and after infusion of the alpha-adrenoceptor antagonist phentolamine (1 mg/kg iv). In untreated diabetic dogs, exercise increased MVo(2) 2.7-fold, coronary blood flow 2.2-fold, and heart rate 2.3-fold. Coronary venous Po(2) fell as MVo(2) increased during exercise. After alpha-adrenoceptor blockade, exercise increased MVo(2) 3.1-fold, coronary blood flow 2.7-fold, and heart rate 2.1-fold. Relative to untreated diabetic dogs, alpha-adrenoceptor blockade significantly decreased the slope of the relationship between coronary venous Po(2) and MVo(2). The difference between the untreated and phentolamine-treated slopes was greater in the diabetic dogs than in the nondiabetic dogs. In addition, the decrease in coronary blood flow to intracoronary norepinephrine infusion was significantly augmented in anesthetized, open-chest, beta-adrenoceptor-blocked diabetic dogs compared with the nondiabetic dogs. These findings demonstrate that alpha-adrenoceptor-mediated coronary vasoconstriction is augmented in alloxan-induced diabetic dogs during physiological increases in MVo(2).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
8750-7587
pubmed:author
pubmed:issnType
Print
pubmed:volume
97
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
431-8
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:14978008-Adrenergic alpha-Agonists, pubmed-meshheading:14978008-Adrenergic alpha-Antagonists, pubmed-meshheading:14978008-Adrenergic beta-Antagonists, pubmed-meshheading:14978008-Animals, pubmed-meshheading:14978008-Blood Gas Analysis, pubmed-meshheading:14978008-Coronary Vessels, pubmed-meshheading:14978008-Diabetes Mellitus, Experimental, pubmed-meshheading:14978008-Dogs, pubmed-meshheading:14978008-Dose-Response Relationship, Drug, pubmed-meshheading:14978008-Female, pubmed-meshheading:14978008-Hemodynamics, pubmed-meshheading:14978008-Male, pubmed-meshheading:14978008-Myocardium, pubmed-meshheading:14978008-Norepinephrine, pubmed-meshheading:14978008-Oxygen Consumption, pubmed-meshheading:14978008-Phentolamine, pubmed-meshheading:14978008-Physical Exertion, pubmed-meshheading:14978008-Propranolol, pubmed-meshheading:14978008-Receptors, Adrenergic, alpha, pubmed-meshheading:14978008-Vasoconstriction
pubmed:year
2004
pubmed:articleTitle
Alpha-adrenoceptor-mediated coronary vasoconstriction is augmented during exercise in experimental diabetes mellitus.
pubmed:affiliation
Departnment Integrative of Physiology, University of North Texas Health Sciences Center, Fort Worth, Texas 76107-2699, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't